Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients

References

• Tallman M S, Gilliland D G, Rowe J M. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154–1163
   PubMed Web of Science ®Google Scholar
• Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, et al. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gann 1977; 68: 685–690
   PubMedGoogle Scholar
• Norgaard J M, Bukh A, Langkjer S T, Clausen N, Palshof T, Hokland P. MDR1 gene expression and drug resistance of AML cells. Br J Haematol 1998; 100: 534–540
   PubMed Web of Science ®Google Scholar
• Hansen O P, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen A M, Christensen B E, et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 1991; 5: 510–516
   PubMed Web of Science ®Google Scholar
• Oberg G, Killander A, Bjoreman M, Gahrton G, Grimfors G, Gruber A, et al. Long-term follow-up of patients ≥ 60 yr old with acute myeloid leukaemia treated with intensive chemotherapy. Eur J Haematol 2002; 68: 376–381
   PubMed Web of Science ®Google Scholar
• Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi J I, Ishida T. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res 1977; 37: 2481–2486
   PubMed Web of Science ®Google Scholar
• Ohno R, Kato Y, Nagura E, Murase T, Okumura M, Yamada H, et al. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. J Clin Oncol 1986; 4: 1740–1747
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common toxicity criteria. M D Bethesda. National Cancer Institute. 1999
   Google Scholar
• Kaplan E L, Meire P. Nonparameric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Stone R M. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol 2002; 39: 4–10
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004; 89: 998–1008
   PubMed Web of Science ®Google Scholar
• Keating M J, Kantarjian H, Smith T L, Estey E, Walters R, Andersson B, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071–1080
   PubMed Web of Science ®Google Scholar
• Estey E H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000; 14: 476–479
   PubMed Web of Science ®Google Scholar
• Karanes C, Kopecky K J, Head D R, Grever M R, Hynes H E, Kraut E H, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 1999; 23: 787–794
   PubMed Web of Science ®Google Scholar
• Mahadevan D, List A F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004; 104: 1940–1951
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol 1996; 14: 204–213
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Kobayashi T, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, et al. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group. Int J Hematol 1999; 70: 56–57
   PubMed Web of Science ®Google Scholar
• Rowe J M, Chang A Y, Bennett J M. Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood 1988; 71: 992–996
   PubMed Web of Science ®Google Scholar
• Kern W, Braess J, Grote-Metke A, Kuse H, Fuchs R, Hossfeld D K, et al. Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. Leukemia 1998; 12: 1522–1526
   PubMed Web of Science ®Google Scholar
• Usui N, Dobashi N, Kobayashi T, Yano S, Maki N, Asai O, et al. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. J Clin Oncol 1998; 16: 2086–2092
   PubMed Web of Science ®Google Scholar
• Usui N, Dobashi N, Asai O, Yano S, Yahagi Y, Saito T, et al. Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia. Int J Hematol 2002; 76: 436–445
   PubMed Web of Science ®Google Scholar
• Ohno R. Current progress in the treatment of adult acute leukemia in Japan. Jpn J Clin Oncol 1993; 23: 85–97
   PubMed Web of Science ®Google Scholar